• 대한본초학회지
• /
• 제35권1호
• /
• pp.19-25
• /
• 2020

Objects : The daily dose of Pinelliae Tuber in ≪Treatise on Cold Damage Diseases≫ is half seung in volume, two and half ryang in weight, and fifteen in total number. But the daily dose should be a whole number. So I found out the background of this setting and correct solution. Methods : I searched Classics of Traditional Medicine, found out the background of the daily dose setting, solution. Results : The daily dose of Pinelliae tuber in ≪Hangdi's Internal Classic Miraculous Pivot≫, ≪Bohenggyuljangbuyongyakbeobyo≫ is half seung. ≪Treatise on Cold Dameage Diseases≫ followed the same daily dose of that because it referred to these books. In ≪Synopsis of Prescription of the Golden Chamber≫, the daily dose of that is half seung, one or two seung. The half seung of the Pinelliae Tuber is thirty three mL, but the diameter is 1~1.5 cm that accurate measurement by volume is difficult. The daily dose by weight is correct considering the unity of marking of the daily dose, accuracy of measurement, the fact that Pinelliae Tuber is currently distributed by cutting. So, two ryang is correct which is thirteen gram. Conclusions : Considering the traditionality, the convenience of measurement, the daily dose of Pinelliae Tuber in the ≪Treatise on Cold Damage Diseases≫ is half seung, but considering the unity, accuracy, current state of distribution, it is correct that the daily dose of it is two ryang. It corresponds to thirteen gram.

• 한국방사선학회논문지
• /
• 제9권5호
• /
• pp.287-293
• /
• 2015

식도암은 병변의 길이가 길고 깊이의 불균질성으로 인하여 방사선의 균일한 선량분포를 얻기 어렵다. 이러한 문제점을 개선해 보고자 Half beam 법을 이용하여 선량분포의 균질성을 극복해 보고자 환자의 영상을 바탕으로 하여 Normal beam과 Half beam을 이용하여 각각 치료계획을 세워 표적체적포함율과 선량체적곡선, 일치성지수와 균질성지수를 상호 비교하고, 인접정상장기인 심장, 척수, 폐를 비교해 보고자 한다. 실험결과 Half beam을 이용한 치료계획이 표적체적포함율과 선량체적곡선 그리고 일치성지수와 균질성지수가 우수하였으며 정상조직 보호측면에서도 미미하지만 우수한 것으로 나타났다. 하지만 정확한 환자자세가 확보되지 않으면 부작용이 발생할 수 있다. 따라서, 기하학적으로 정확한 환자의 위치잡이를 수반한 Half beam의 적용은 선량적으로 유용할 수 있을 것으로 사료된다.

• 대한핵의학회지
• /
• 제9권1호
• /
• pp.59-71
• /
• 1975

53 patients with hyperthyroidism have been analyzed with special reference to therapeutic response to radioactive iodine ($^{131}I$) treatment. Mean effective half-life, 24 hour uptake rate and radiation dose of $^{131}I$ in hyperthyroid patients included in this study were respectively. 1. Mean effective half-life of $^{131}I\;was\;4.7{\pm}1.5$ days in the tracer dose and $5.0{\pm}1.5$ days in the therapeutic dose. 2. Mean 24 hour uptake rate of $^{131}I\;was\;72.7{\pm}11.1%$ in the tracer dose and $73.4{\pm}12.3%$ in the theapeutic dose. 3. Mean radiation dose of $^{131}I\;was\;5,319{\pm}2,648$ RAD as predicted and $5,692{\pm}2,843$ RAD as actual. A single dose of radioactive iodine treatment was satisfactory in 34 patients (radioiodine sensitive) and multiple doses of radioactive iodine treatments were required in 19 patients (radioiodine resistant). A radioiodine resistant group of patients with hyperthyroidism was distinctively characteristic in the following aspects. 1. Mean thyroid weight calculated in the resistant group ($63.9{\pm}14.0gm$) was significantly (p<0.01) greater than that of the sensitive group ($46.6{\pm}13.3gm$). 2. Mean 24 hour uptake rate of the tracer dose in the resistant group ($67.3{\pm}10.7%$) was significantly (p<0.01) lower than that of the sensitive group ($75.7{\pm}10.5%$). 3. Mean 24 hour uptake rate of the therapeutic dose in the resistant group ($68.5{\pm}13.7%$) was significantly (p<0.05) lower than that of the sensitive group ($76.1{\pm}10.9%$). 4. Mean predicted radiation dose, of $^{131}I$ in the resistant group ($3,684{\pm}1,745$ RAD) was significantly (p<0.01) lower than that of the sensitive group ($6,232{\pm}2,683$ RAD). 5. Mean actual radiation dose of $^{131}I$ in the resistant group ($4,100{\pm}1,691$ RAD) was significantly (p<0.01) lower than that of the sensitive group ($6,582{\pm}3,024$ RAD). 6. No significant difference was detected in terms of effective half-life of $^{131}I$ among the groups (p>0.05). 7. The average mean % difference of effective half-life, uptake rate and radiation dose measured following the tracer and therapeutic dose of $^{131}I$ were not statistically significant (p>0.05). Therefore effective half-life, uptake rate and radiation dose of the therapeutic dose of $^{131}I$ were readily predictable following the tracer dose of $^{131}I$. 8. It is concluded that the possibility of resistance to radioactive iodine treatment may be anticipated in patients with thyroid gland large in size and compromised $^{131}I$ uptake rate.

• 핵의학기술
• /
• 제18권1호
• /
• pp.98-103
• /
• 2014

갑상선 분화암 환자의 방사선 치료에서 I-131의 유효반감기는 환자에게 투여하는 양의 계산뿐만 아니라 환자의 격리 입원기간의 결정, 환자로부터 가족들이 받게 되는 선량을 계산하는데 유용한 값이다. 하지만 이 값은 물리적반감기와는 달리 실측을 해야만 얻을 수 있어 입원 격리중인 환자에게 계측하기가 기술적으로 어려운 문제가 있다. Dual time I-131 whole body scan의 초기촬영과 지연촬영 사이의 체내잔류방사능량을 이용하여 전신과 갑상선에 유효반감기를 추정해 보았다. 또한 혈중 크레아티닌 농도, GFR, 투여량이 유효반감기와 상관관계가 있는지 알아보았다. 유효반감기 측정을 위해 전신에 체내잔류방사능량과 갑상선의 잔류방사능량을 측정하기 위해 환자의 전신을 흥미영역으로 설정한 후 배후방사능을 보정하여 전신의 체내잔류방사능량을 획득하였고, 갑상선 부위에 ROI를 설정한 후 배후 방사능을 보정하여 갑상선의 잔류방사능량을 획득하였다. 초기영상과 지연영상의 측정값 사이의 비율을 계산하여 전신과 갑상선의 유효반감기를 구하였다. 또한 유효반감기와 GFR, 혈중크레아티닌 농도, I-131 투여량과의 상관관계를 분석하였다. 전신의 체내잔류방사능량을 측정한 값의 유효반감기는 $17.06{\pm}5.50$시간으로 나타났고 갑상선의 잔류방사능량을 측정한 값의 유효반감기는 $17.22{\pm}5.41$시간으로 나타났으며 두 유효반감기는 유의한 차이를 보이지 않았다(P=0.887). GFR 값이 올라갈수록 전신의 유효반감기(r=-0.407, P=0.003)와 갑상선 유효반감기(r=-0.473, P=0.001) 모두 유의하게 감소하였으며 혈중크레아티닌 농도가 올라갈수록 전신의 유효반감기(r=0.309, P=0.029)와 갑상선 유효반감기(r=0.371, P=0.008) 모두 유의하게 증가하였다. 투여량은 두유효반감기와 상관관계를 보이지 않았다. 본 연구를 통해 고용량 방사성요오드 치료환자 입원기간의 최적화 연구와 기존 유효반감기를 구하기 위해 종사자의 피폭 및 복잡성을 보완하여 간편하게 측정을 할 수 있을 것이라 생각한다. 또한 분석된 갑상선의 유효반감기를 적용한 MIRD schema의 내부피폭선량 평가 연구에도 활용할 수 있을 것으로 사료된다.

• 한국임상수의학회지
• /
• 제34권1호
• /
• pp.18-22
• /
• 2017

The aim of this study was to prove that the hypothesis of half dose (HD) allergen-specific immunotherapy (ASIT) in the treatment of canine atopic dermatitis (CAD) would result in a similar success rate compared to the standard dose (SD) ASIT. Clinical signs were evaluated using a third version of the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) prior to ASIT (day 0), at the end of induction (day 43), and at three month afterwards (day 90). Of the 18 atopic dogs, 12 dogs (SD group: 6; HD group: 6) had a good - excellent response to the house dust mites-specific immunotherapy. The efficacies of ASIT were 66.6% in both groups. The grades of reduction rate CADESI-03 were not different between two groups. Therefore, half dose protocol of house dust mites-specific immunotherapy is an effective and efficient method to treat CAD.

• Tuberculosis and Respiratory Diseases
• /
• 제84권2호
• /
• pp.134-139
• /
• 2021

Background: Intrapleural urokinase is one of the most widely used fibrinolytic agents in the treatment of complicated parapneumonic effusion (CPPE). However, little research has been performed on the optimal urokinase dosage. The aim of this study was to evaluate the treatment efficacy of half dose urokinase compared with conventional dose urokinase. Methods: We retrospectively enrolled 92 patients with CPPE or empyema who underwent intrapleural urokinase treatment at two tertiary hospitals. Patients received antibiotics, chest tube drainage, and other treatments as part of routine care. The primary outcome was the treatment success rate in the half dose urokinase group (50,000 IU daily for maximal 6 days) and the conventional dose urokinase group (100,000 IU daily). Treatment success was defined as clinical and radiological improvements without surgical treatment or re-admission within one month. Results: Forty-four patients received half dose urokinase, whereas 48 patients were treated with conventional dose urokinase. Both groups were relatively well matched at baseline, excluding higher serum white blood cell count and higher empyema prevalence in the half dose urokinase group. The treatment success rate was not different between the two groups (p=0.048). There were no differences in the rate of in-hospital death and surgical treatment, hospitalization duration, and indwelling catheter duration. In the multivariate analysis, urokinase dose was not a predictor of treatment success. Conclusion: Half dose intrapleural urokinase is equally effective conventional dose urokinase in treating patients with CPPE or empyema.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 2003년도 Annual Meeting of KSAP : International Symposium on Pharmaceutical and Biomedical Sciences on Obesity
• /
• pp.108-108
• /
• 2003

The current study was performed to observe the effects of Panax ginseng (PG) and P. quinquefolia (PQ) on hemodynamics such as blood flow rate (BF), blood flow velocity (BV), heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP, and body temperature (BT) in healthy young men. After testing equality of variance, Student's t-test using PROC TTEST was examined to. prove statistical differences between control and ginseng conditions at each time point. It was found that the BF data were fluctuated by personal deviation. In order to minimize the deviation, the results obtained for 6 hrs were reconstituted after dividing them into two periods of the first half from 1 to 3 hrs and of the latter half from 3.5 to 6 hrs. And then the reconstitution data and dose-response curves were obtained. Blood flow such as BF and BV shows significant increases both two periods in the dose of PG 2.25 and PG 9.0, whereas significant decrease in the dose of PG 4.5. However, in the PQ groups, the middle dose PQ 4.5 shows the highest significant increase among the three doses. Except for PG 2.25 in HR, other doses show significant decreases both in the first half and latter half. SBP of PQ 9.0 shows only a significant decrease in the first half; on the other hand, in the latter half, PG 4.5, PG 9.0 and PQ 9.0 significantly increase SBP. In addition, DBP of PG 2.25 and PG 4.5 show significant increase in the both periods. In the BT, PQ groups show gradual decrease from PQ 2.25 to PQ 9.0; however, PG groups show differently. PG 4.5 shows significant decrease, but PG 9.0 shows a increase without statistical meanings. In summary, PG is more effective in respect to keeping homeostasis of hemodynamics.

• Journal of Chest Surgery
• /
• 제24권3호
• /
• pp.253-260
• /
• 1991

The adequacy of anticoagulation with heparin during cardiopulmonary bypass, and precise neutralization with protamine at the conclusion of cardiopulmonary bypass, were important. In sixty children undergoing cardiopulmonary bypass, ACT and heparin dose-response curve were studied. Total dose of heparin before bypass were 2.80$\pm$0.74 mg/kg and the amount of protamine administered after bypass were 3.0$\pm$1.23 mg/kg. So protamine: heparin ratio was 1.07: l.c After administration of protamine which dose is calculated with heparin dose-response curve, ACTs were returned to normal range[mean 114.8 $\pm$13 second]. The heparin sensitivity and its half-life do not have relationship with age, weight, height, surface area and urine amount during operation. And there are too much individual variations in heparin sensitivity and its half-life. So conventional heparin protocols can overestimate or underestimate the amount of heparin and protamine. Heparin dose-response curve makes it possible to maintain anticoagulation in a safe range during bypass with adequate amount of heparin individually. At the conclusion of bypass, this curve can be used to predict the precise amount of protamine amount of protamine needed for neutralization of the heparin. But heparin dose-response curve to be used clinically, further studies will be needed about relationship between ACT and heparin level in the high range, influence of hemodilution and hypothermia to ACT and discrepancy between true adequate amount of protamine and calculated amount by heparin dose-response curve.

• Biomolecules & Therapeutics
• /
• 제6권4호
• /
• pp.400-405
• /
• 1998

The pharmacokinetics of CJ-50001 (recombinant human granulocyte-colony stimulating factor, developed by R&D center of Cheil Jedang Corp.) were investigated in rats and dogs. The serum concentrations of CJ-50001 were measured by a sandwich enzyme immunoassay. After single intravenous (iv) administration of Cf-50001 to rats at a dose of 5 $\mu$g/kg, the mean terminal half-life and area under the concentration-time curve (AUC) were 0.96 h and 124.497g . h/ml, respectively. After single subcutaneous (sc) administration at the same dose, maximum serum concentration was observed at about 2 hours after administration, and the mean terminal half-life, AUC and the bioavailability were 1.11 h,63.58$\mu$g . h/ml and 51.07%, respectively. In repeated dosing studies, CJ-50001 was administered iv and sc to rats at a daily dose of 5$\mu$g/kg for 7 days. The pharmacokinetic parameters, such as mean AUC and terminal half-life, were no significantly different from those of single administration. Following single iv and sc administration of CJ-50001 to dogs at a dose of 5 $\mu$g/kg, mean AUCs were much higher than those of rats, due to the decreased clearence (CL). After sc administration to dogs, maximum serum concentration was observed at 2~4 hours after administration and the bioavailability was 54.60%.

• 한국환경농학회지
• /
• 제28권3호
• /
• pp.281-288
• /
• 2009

Azoxystrobin과 kresoxim-methyl의 참외 중 반감기와 잔류양상을 조사하였다. Azoxystrobin의 참외 중 0일차 잔류량은 기준량 및 배량 처리구에서 각각 0.09 및 0.14 mg/kg으로 나타났으며 농약의 반감기 소실곡선식은 y=0.0766e$^{-0.138x}$ ($r^2$=0.9424) 및 y=0.1143e$^{-0.0890x}$ ($r^2$=0.9310) 이었으며 생물학적 반감기는 각각 5.0일 및 7.8일 이었다. Kresoxim-methyl의 참외 중 0일차 잔류량은 기준량 및 배량 처리구에서 각각 0.10 및 0.23 mg/kg으로 나타났으며 농약의 소실곡선식은 y=0.0896e$^{-0.1672x}$ ($r^2$=0.9428) 및 y=0.1504e$^{-0.1446x}$ ($r^2$=0.9040) 이었고 생물학적인 반감기는 각각 4.1일 및 4.8일 이었다. 재배기간 중 참외의 무게증가에 농약희석효과를 배제한 절대잔류농도는 약제 살포 후 14일 경과시 azoxystrobin은 기준량 및 배량에서 0.01 및 0.05 mg/kg으로서 각각 83.6 및 67%의 농약이 분해되었다. Kresoxim-methyl은 각각 0.01 및 0.03 mg/kg 으로서 86.2 및 87.8% 정도의 농약 분해율을 보였다.